CL2013000201A1 - Composiciones farmaceuticas combinadas que comprenden una forma activada potenciada de anticuerpos contra la proteina s-100 de cerebro y una forma activada potenciada de anticuerpos contra nos endotelial; metodo de tratamiento del vertigo la cinetosis y la distonia vegetativa-vascular. - Google Patents
Composiciones farmaceuticas combinadas que comprenden una forma activada potenciada de anticuerpos contra la proteina s-100 de cerebro y una forma activada potenciada de anticuerpos contra nos endotelial; metodo de tratamiento del vertigo la cinetosis y la distonia vegetativa-vascular.Info
- Publication number
- CL2013000201A1 CL2013000201A1 CL2013000201A CL2013000201A CL2013000201A1 CL 2013000201 A1 CL2013000201 A1 CL 2013000201A1 CL 2013000201 A CL2013000201 A CL 2013000201A CL 2013000201 A CL2013000201 A CL 2013000201A CL 2013000201 A1 CL2013000201 A1 CL 2013000201A1
- Authority
- CL
- Chile
- Prior art keywords
- antibodies against
- activated form
- enhanced activated
- vertigo
- vegetative
- Prior art date
Links
- 208000014094 Dystonic disease Diseases 0.000 title 1
- 102100028452 Nitric oxide synthase, endothelial Human genes 0.000 title 1
- 101710090055 Nitric oxide synthase, endothelial Proteins 0.000 title 1
- 102000013674 S-100 Human genes 0.000 title 1
- 108700021018 S100 Proteins 0.000 title 1
- 208000012886 Vertigo Diseases 0.000 title 1
- 210000004556 brain Anatomy 0.000 title 1
- 208000010118 dystonia Diseases 0.000 title 1
- 201000003152 motion sickness Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 231100000889 vertigo Toxicity 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Alternative & Traditional Medicine (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2010130356/15A RU2542453C2 (ru) | 2010-07-21 | 2010-07-21 | Лекарственное средство и способ лечения вегето-сосудистой дистонии, синдрома головокружения различного генеза и кинетозов |
| RU2010130353/15A RU2542445C2 (ru) | 2010-07-21 | 2010-07-21 | Лекарственное средство для лечения болезни альцгеймера и способ лечения болезни альцгеймера |
| RU2011127052/15A RU2503462C2 (ru) | 2011-07-01 | 2011-07-01 | Способ лечения головокружения различного генеза, кинетозов и вегето-сосудистой дистонии (варианты) и лекарственное средство |
| RU2011127058/15A RU2536232C2 (ru) | 2011-07-01 | 2011-07-01 | Лекарственное средство для лечения болезни альцгеймера и способ лечения болезни альцгеймера |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2013000201A1 true CL2013000201A1 (es) | 2015-01-23 |
Family
ID=44899157
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2013000201A CL2013000201A1 (es) | 2010-07-21 | 2013-01-21 | Composiciones farmaceuticas combinadas que comprenden una forma activada potenciada de anticuerpos contra la proteina s-100 de cerebro y una forma activada potenciada de anticuerpos contra nos endotelial; metodo de tratamiento del vertigo la cinetosis y la distonia vegetativa-vascular. |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20130058981A1 (enExample) |
| EP (1) | EP2596018A2 (enExample) |
| JP (2) | JP2013536174A (enExample) |
| KR (1) | KR20130102542A (enExample) |
| CN (1) | CN103124741A (enExample) |
| AR (1) | AR082314A1 (enExample) |
| AU (1) | AU2011281248B2 (enExample) |
| BR (1) | BR112013001296A2 (enExample) |
| CA (1) | CA2805985A1 (enExample) |
| CL (1) | CL2013000201A1 (enExample) |
| DE (1) | DE112011102397T5 (enExample) |
| EA (1) | EA029998B1 (enExample) |
| ES (1) | ES2446643R1 (enExample) |
| FR (1) | FR2962910A1 (enExample) |
| GB (1) | GB2496342B (enExample) |
| IL (1) | IL224336A (enExample) |
| IT (1) | ITTO20110630A1 (enExample) |
| MX (1) | MX355371B (enExample) |
| NZ (1) | NZ606988A (enExample) |
| PE (1) | PE20131065A1 (enExample) |
| PH (1) | PH12013500141A1 (enExample) |
| SG (2) | SG187160A1 (enExample) |
| WO (1) | WO2012010974A2 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2181297C2 (ru) * | 2000-06-20 | 2002-04-20 | Эпштейн Олег Ильич | Способ лечения патологического синдрома и лекарственное средство |
| UA76638C2 (en) | 2002-08-02 | 2006-08-15 | Oleh Illich Epshtein | Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon |
| RU2309732C1 (ru) * | 2006-03-13 | 2007-11-10 | Олег Ильич Эпштейн | Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата |
| MX2013000543A (es) * | 2010-07-15 | 2013-10-28 | Oleg Iliich Epshtein | Un metodo para aumentar el efecto de una forma activa potenciada de un anticuerpo. |
| EA029400B1 (ru) | 2010-07-15 | 2018-03-30 | Олег Ильич ЭПШТЕЙН | Фармацевтическая композиция для лечения ожирения и сопутствующих метаболических расстройств и способ лечения |
| FR2962652A1 (fr) | 2010-07-15 | 2012-01-20 | Oleg Iliich Epshtein | Composition pharmaceutique d'association et son utilisation dans des procedes pour traiter les maladies ou affections associees a des maladies neurodegeneratives |
| PH12013500144A1 (en) | 2010-07-21 | 2018-03-21 | Oleg Iliich Epshtein | A method of treating attention deficit hyperactivity disorder |
| FR2962909A1 (fr) * | 2010-07-21 | 2012-01-27 | Oleg Iliich Epshtein | Composition pharmaceutique d'association et son utilisation dans des procedes pour traiter les maladies ou affections associees avec une maladie ou affection respiratoire |
| CN103118707A (zh) * | 2010-07-21 | 2013-05-22 | 奥列格·伊里奇·爱泼斯坦 | 复合药物组合物及对糖尿病和代谢紊乱进行治疗的方法 |
| WO2012010978A2 (en) * | 2010-07-21 | 2012-01-26 | Oleg Iliich Epshtein | A method of treating alzheimer's disease |
| CZ2013159A3 (cs) * | 2010-08-06 | 2013-06-12 | Iliich Epshtein@Oleg | Kombinovaná farmaceutická kompozice a zpusoby lécby a prevence infekcních chorob |
| RU2013111962A (ru) | 2013-03-18 | 2014-09-27 | Олег Ильич Эпштейн | Способ определения выраженности модифицирующей активности, ассоциированной с носителем |
| RU2013111961A (ru) | 2013-03-18 | 2014-09-27 | Олег Ильич Эпштейн | Способ определения выраженности модифицирующей активности, ассоциированной с носителем |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4311897A (en) | 1979-08-28 | 1982-01-19 | Union Carbide Corporation | Plasma arc torch and nozzle assembly |
| RU2113230C1 (ru) | 1996-04-03 | 1998-06-20 | Ильчиков Михаил Захарович | Седативное лекарственное средство "авиаморе" |
| US6150500A (en) * | 1996-07-12 | 2000-11-21 | Salerno; John C. | Activators of endothelial nitric oxide synthase |
| US5849528A (en) * | 1997-08-21 | 1998-12-15 | Incyte Pharmaceuticals, Inc.. | Polynucleotides encoding a human S100 protein |
| RU2156621C1 (ru) * | 1999-03-04 | 2000-09-27 | Эпштейн Олег Ильич | Нейротропное лекарственное средство |
| RU2181297C2 (ru) * | 2000-06-20 | 2002-04-20 | Эпштейн Олег Ильич | Способ лечения патологического синдрома и лекарственное средство |
| US20030087250A1 (en) * | 2001-03-14 | 2003-05-08 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer |
| RU2201255C1 (ru) * | 2001-12-26 | 2003-03-27 | Эпштейн Олег Ильич | Лекарственное средство и способ регуляции сосудистого тонуса |
| UA76638C2 (en) | 2002-08-02 | 2006-08-15 | Oleh Illich Epshtein | Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon |
| UA76639C2 (uk) * | 2002-08-02 | 2006-08-15 | Олєг Ільіч Епштєйн | Гомеопатичний лікарський засіб та спосіб лікування еректильних дисфункцій |
| UA76641C2 (uk) * | 2002-08-02 | 2006-08-15 | Олєг Ільіч Епштєйн | Гомеопатичний лікарський засіб та спосіб лікування захворювань передміхурової залози |
| AU2003295328A1 (en) * | 2002-10-02 | 2004-04-23 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| GB2414670B (en) | 2003-03-14 | 2008-03-19 | Nutrition Res Inc | Homeopathic formulations useful for treating pain and/or inflammation |
| EA029400B1 (ru) * | 2010-07-15 | 2018-03-30 | Олег Ильич ЭПШТЕЙН | Фармацевтическая композиция для лечения ожирения и сопутствующих метаболических расстройств и способ лечения |
| FR2962652A1 (fr) * | 2010-07-15 | 2012-01-20 | Oleg Iliich Epshtein | Composition pharmaceutique d'association et son utilisation dans des procedes pour traiter les maladies ou affections associees a des maladies neurodegeneratives |
| MX2013000543A (es) * | 2010-07-15 | 2013-10-28 | Oleg Iliich Epshtein | Un metodo para aumentar el efecto de una forma activa potenciada de un anticuerpo. |
| FR2962909A1 (fr) * | 2010-07-21 | 2012-01-27 | Oleg Iliich Epshtein | Composition pharmaceutique d'association et son utilisation dans des procedes pour traiter les maladies ou affections associees avec une maladie ou affection respiratoire |
| WO2012014078A2 (en) * | 2010-07-21 | 2012-02-02 | Olge Iliich Epshtein | Method of treatment of organic diseases of nervous system, psychoorganic syndrome and encephalopathy |
| WO2012010978A2 (en) * | 2010-07-21 | 2012-01-26 | Oleg Iliich Epshtein | A method of treating alzheimer's disease |
| PH12013500144A1 (en) * | 2010-07-21 | 2018-03-21 | Oleg Iliich Epshtein | A method of treating attention deficit hyperactivity disorder |
| CN103118707A (zh) * | 2010-07-21 | 2013-05-22 | 奥列格·伊里奇·爱泼斯坦 | 复合药物组合物及对糖尿病和代谢紊乱进行治疗的方法 |
-
2011
- 2011-07-15 US US13/135,887 patent/US20130058981A1/en not_active Abandoned
- 2011-07-15 CN CN2011800454598A patent/CN103124741A/zh active Pending
- 2011-07-15 DE DE112011102397T patent/DE112011102397T5/de not_active Withdrawn
- 2011-07-15 IT IT000630A patent/ITTO20110630A1/it unknown
- 2011-07-15 AU AU2011281248A patent/AU2011281248B2/en not_active Ceased
- 2011-07-15 EP EP11773316.2A patent/EP2596018A2/en not_active Ceased
- 2011-07-15 SG SG2013004809A patent/SG187160A1/en unknown
- 2011-07-15 JP JP2013520240A patent/JP2013536174A/ja active Pending
- 2011-07-15 ES ES201390010A patent/ES2446643R1/es active Pending
- 2011-07-15 MX MX2013000805A patent/MX355371B/es active IP Right Grant
- 2011-07-15 PE PE2013000111A patent/PE20131065A1/es not_active Application Discontinuation
- 2011-07-15 SG SG10201505676RA patent/SG10201505676RA/en unknown
- 2011-07-15 WO PCT/IB2011/002378 patent/WO2012010974A2/en not_active Ceased
- 2011-07-15 EA EA201300127A patent/EA029998B1/ru not_active IP Right Cessation
- 2011-07-15 GB GB1302925.1A patent/GB2496342B/en not_active Expired - Fee Related
- 2011-07-15 BR BR112013001296A patent/BR112013001296A2/pt not_active IP Right Cessation
- 2011-07-15 FR FR1156477A patent/FR2962910A1/fr not_active Withdrawn
- 2011-07-15 NZ NZ606988A patent/NZ606988A/en not_active IP Right Cessation
- 2011-07-15 PH PH1/2013/500141A patent/PH12013500141A1/en unknown
- 2011-07-15 CA CA2805985A patent/CA2805985A1/en not_active Abandoned
- 2011-07-15 KR KR1020137004331A patent/KR20130102542A/ko not_active Ceased
- 2011-07-21 AR ARP110102644A patent/AR082314A1/es unknown
-
2013
- 2013-01-20 IL IL224336A patent/IL224336A/en active IP Right Grant
- 2013-01-21 CL CL2013000201A patent/CL2013000201A1/es unknown
-
2016
- 2016-07-01 JP JP2016131718A patent/JP2016199571A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013536174A (ja) | 2013-09-19 |
| GB201302925D0 (en) | 2013-04-03 |
| CA2805985A1 (en) | 2012-01-26 |
| ES2446643R1 (es) | 2015-03-06 |
| CN103124741A (zh) | 2013-05-29 |
| JP2016199571A (ja) | 2016-12-01 |
| DE112011102397T5 (de) | 2013-05-08 |
| AU2011281248B2 (en) | 2017-02-02 |
| US20130058981A1 (en) | 2013-03-07 |
| AU2011281248A1 (en) | 2013-03-14 |
| KR20130102542A (ko) | 2013-09-17 |
| MX355371B (es) | 2018-04-17 |
| EP2596018A2 (en) | 2013-05-29 |
| EA029998B1 (ru) | 2018-06-29 |
| FR2962910A1 (fr) | 2012-01-27 |
| IL224336A (en) | 2017-06-29 |
| GB2496342B (en) | 2017-12-06 |
| WO2012010974A3 (en) | 2012-04-19 |
| SG10201505676RA (en) | 2015-08-28 |
| PH12013500141A1 (en) | 2013-03-11 |
| PE20131065A1 (es) | 2013-09-23 |
| ITTO20110630A1 (it) | 2012-01-22 |
| ES2446643A2 (es) | 2014-03-10 |
| NZ606988A (en) | 2015-08-28 |
| WO2012010974A2 (en) | 2012-01-26 |
| MX2013000805A (es) | 2013-10-28 |
| BR112013001296A2 (pt) | 2017-12-19 |
| WO2012010974A8 (en) | 2013-04-25 |
| GB2496342A (en) | 2013-05-08 |
| SG187160A1 (en) | 2013-02-28 |
| EA201300127A1 (ru) | 2013-12-30 |
| AR082314A1 (es) | 2012-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2013000201A1 (es) | Composiciones farmaceuticas combinadas que comprenden una forma activada potenciada de anticuerpos contra la proteina s-100 de cerebro y una forma activada potenciada de anticuerpos contra nos endotelial; metodo de tratamiento del vertigo la cinetosis y la distonia vegetativa-vascular. | |
| UA109650C2 (xx) | Біс-арилзв'язані арилтриазолони та їх застосування | |
| ME03008B (me) | Terapija na osnovu proteina i dijagnoza patologije u којој posreduje tau u alcнajмerovoj bolesti | |
| BR112014023937A2 (pt) | composição farmacêutica, agente farmacêutico de combinação e método de tratamento | |
| BR112014002621A2 (pt) | anticorpo, composição farmacêutica, combinação farmacêutica, dna e método de tratamento | |
| BR112014021103A8 (pt) | anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo | |
| SMT201600398B (it) | Inibitori di proteina chinasi (varianti), uso di questi nel trattamento di malattie oncologiche e composizione farmaceutica basata su questi | |
| BR112015002524A2 (pt) | derivados de alquilpirimidina para o tratamento de infecções virais e outras doenças. | |
| EA201291336A1 (ru) | Замещенные 5-фтор-1н-пиразолопиридины и их применение | |
| EP3072536A4 (en) | Hydrophilic electrospinning biological composite stent material used for tissue regeneration and preparation method and application thereof | |
| EP2542255A4 (en) | METHOD AND COMPOSITIONS FOR TREATING THE DEGOS SYNDROME | |
| IL235966B (en) | Aqueous compositions with a ph level of 6 containing anti-Baffr antibody without fucosylation for use in the treatment of autoimmune diseases | |
| BR112013029187A2 (pt) | método e sistema para estabelecimento do formato da cavidade de acesso à oclusão no tratamento endodôntico | |
| CL2013000097A1 (es) | Composicion farmaceutica combinada que incluye una forma activada potenciada de un anticuerpo de la proteina s-100 y una forma activada potenciada de un anticuerpo anti tnf-alfa; metodos para el tratamiento de las enfermedades o condiciones funcionales del tracto gastrointestinal. | |
| CY1119518T1 (el) | Τροποποιημενα αντιγονα φυματιωσης | |
| EP2888265A4 (en) | BIVALENT INHIBITORS OF IAP PROTEINS AND THERAPEUTIC PROCEDURES THEREWITH | |
| CR20140224A (es) | Inmunoligantes biespecificos dirigidos contra tnf e il-17 referencia cruzada a solicitudes relacionadas | |
| LT2945642T (lt) | Faktoriaus 1 baltymas, skirtas naudoti ligų gydymui arba prevencijai | |
| BRPI1014027A2 (pt) | suspensão de fármaco de nanopartícula estável. | |
| EP2981551A4 (en) | METHOD AND COMPOSITIONS FOR TREATING MORBUS POMPE | |
| HRP20190318T1 (hr) | Farmaceutski ili kozmetički pripravak za liječenje alopecije | |
| UA107836C2 (uk) | Метод лікування хвороби альцгеймера | |
| BRPI1009418A2 (pt) | nanocapsula de proteina, metodo de pdroduzir uma nanocapsula, e metodo de distribuir uma proteina | |
| IL245183B (en) | Methods of treating and preventing graft versus host disease | |
| CL2013000202A1 (es) | Composicion farmaceutica y combinacion compuesta por una forma potenciada activada de un anticuerpo contra la bradiquinina, una forma potenciada activada de una histamina y una forma potenciada activada de un anticuerpo contra la morfina; metodos para tratar las enfermedades o las condiciones asociadas con la enfermedad o condicion respiratoria. |